Timing of bowel irrigation could ease life after rectal cancer surgery

NCT ID NCT07696689

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study looks at whether starting trans-anal irrigation (a procedure that uses warm water to help empty the bowel) within three months of stoma closure reduces daily bowel movements more than starting later. The trial involves 250 adults who have had rectal cancer surgery and now suffer from low anterior resection syndrome (LARS), which causes frequent, urgent, or uncontrolled bowel movements. Participants are trained to use a device at home and are followed for nine months to track symptoms, quality of life, and satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Water-based transanal irrigation system (Peristeen® Plus device)
What this could lead to
If early irrigation works better, it could establish a new standard timing for managing bowel symptoms after rectal cancer surgery, improving daily comfort and quality of life.
What could go wrong
This is a mid-sized trial comparing two timing strategies, not a new treatment. The benefit may be modest, and individual results vary. The procedure requires daily commitment and may cause discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW ANTERIOR RESECTION SYNDROME (LARS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

constipation disorder Fecal Incontinence Low Anterior Resection Syndrome rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.